Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients

Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients

Qasim Kadhim Farhood,1 Sinan Mohammad Twfeeq21College of Medicine, Babylon University, Babylon; 2Al-Jumhori teaching hospital, Mosul, IraqBackground: This study examined the changes in short-term intraocular pressure (IOP) in a prospective series of patients undergoing intravitreal bevacizumab inje...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Farhood QK, Twfeeq SM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/78ba1d1eec374460b51de96d8af4efd7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:78ba1d1eec374460b51de96d8af4efd7
record_format dspace
spelling oai:doaj.org-article:78ba1d1eec374460b51de96d8af4efd72021-12-02T03:25:45ZShort-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients1177-5483https://doaj.org/article/78ba1d1eec374460b51de96d8af4efd72014-03-01T00:00:00Zhttp://www.dovepress.com/short-term-intraocular-pressure-changes-after-intravitreal-injection-o-a16237https://doaj.org/toc/1177-5483 Qasim Kadhim Farhood,1 Sinan Mohammad Twfeeq21College of Medicine, Babylon University, Babylon; 2Al-Jumhori teaching hospital, Mosul, IraqBackground: This study examined the changes in short-term intraocular pressure (IOP) in a prospective series of patients undergoing intravitreal bevacizumab injection. The aim was to evaluate the frequency and predictive factors related to intraocular pressure (IOP) elevation in patients receiving intravitreal bevacizumab.Patients and methods: This study included 52 patients with diabetic retinopathy between 28 to 75 years of age with a mean age of 51 years; 30 (58%) were females, and 22 (42%) were males. All patients received bevacizumab (1.25 mg/0.05 mL) injected intravitreally in a standard fashion between May 2012 to February 2013 in the AL-Jumhoury teaching hospital. IOP was measured at baseline, 5, 10, and 30 minutes after injection using Goldman applanation tonometry.Statistics: Data were analyzed using the SPSS v.12.0 for windows. Basic, demographic, and clinical data were analyzed using means, proportions, and appropriate 95% confidence intervals (CIs).Results: Most patients (85%) were diagnosed with proliferative diabetic retinopathy, while 15% presented with diabetic macular edema. The mean IOP values at baseline, 5, 10, and 30 minutes after injection were 14.0 mmHg (95% CI 13.4–14.7), 36.1 mmHg (95% CI 33.5–38.6), 25.7 mmHg (95% CI 23.8–27.5), and 15.5 mmHg (95% CI 12.4–16.51), respectively. Regression analysis showed a trend toward phakic patients having higher IOP at 30 minutes.Conclusion: Intravitreal injection of bevacizumab is safe with respect to short-term IOP changes, as almost all IOP returned to a safe range (<25 mmHg) within 30 minutes. Elevated IOP 30 minutes after injection only occurs rarely, so routine prophylactic use of anti-glaucoma medication is not indicated.Keywords: intravitreal injection, bevacizumab, intraocular pressure, Goldmann applanation tonometryFarhood QKTwfeeq SMDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 599-604 (2014)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Farhood QK
Twfeeq SM
Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
description Qasim Kadhim Farhood,1 Sinan Mohammad Twfeeq21College of Medicine, Babylon University, Babylon; 2Al-Jumhori teaching hospital, Mosul, IraqBackground: This study examined the changes in short-term intraocular pressure (IOP) in a prospective series of patients undergoing intravitreal bevacizumab injection. The aim was to evaluate the frequency and predictive factors related to intraocular pressure (IOP) elevation in patients receiving intravitreal bevacizumab.Patients and methods: This study included 52 patients with diabetic retinopathy between 28 to 75 years of age with a mean age of 51 years; 30 (58%) were females, and 22 (42%) were males. All patients received bevacizumab (1.25 mg/0.05 mL) injected intravitreally in a standard fashion between May 2012 to February 2013 in the AL-Jumhoury teaching hospital. IOP was measured at baseline, 5, 10, and 30 minutes after injection using Goldman applanation tonometry.Statistics: Data were analyzed using the SPSS v.12.0 for windows. Basic, demographic, and clinical data were analyzed using means, proportions, and appropriate 95% confidence intervals (CIs).Results: Most patients (85%) were diagnosed with proliferative diabetic retinopathy, while 15% presented with diabetic macular edema. The mean IOP values at baseline, 5, 10, and 30 minutes after injection were 14.0 mmHg (95% CI 13.4–14.7), 36.1 mmHg (95% CI 33.5–38.6), 25.7 mmHg (95% CI 23.8–27.5), and 15.5 mmHg (95% CI 12.4–16.51), respectively. Regression analysis showed a trend toward phakic patients having higher IOP at 30 minutes.Conclusion: Intravitreal injection of bevacizumab is safe with respect to short-term IOP changes, as almost all IOP returned to a safe range (<25 mmHg) within 30 minutes. Elevated IOP 30 minutes after injection only occurs rarely, so routine prophylactic use of anti-glaucoma medication is not indicated.Keywords: intravitreal injection, bevacizumab, intraocular pressure, Goldmann applanation tonometry
format article
author Farhood QK
Twfeeq SM
author_facet Farhood QK
Twfeeq SM
author_sort Farhood QK
title Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
title_short Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
title_full Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
title_fullStr Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
title_full_unstemmed Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
title_sort short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/78ba1d1eec374460b51de96d8af4efd7
work_keys_str_mv AT farhoodqk shorttermintraocularpressurechangesafterintravitrealinjectionofbevacizumabindiabeticretinopathypatients
AT twfeeqsm shorttermintraocularpressurechangesafterintravitrealinjectionofbevacizumabindiabeticretinopathypatients
_version_ 1718401801391177728

Ejemplares similares